Zurcher Kantonalbank Zurich Cantonalbank Raises Holdings in Pfizer Inc. $PFE

Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 16.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 3,469,549 shares of the biopharmaceutical company’s stock after acquiring an additional 496,399 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Pfizer were worth $86,392,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of PFE. Triad Wealth Partners LLC boosted its holdings in Pfizer by 1.9% in the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after acquiring an additional 386 shares during the period. ETF Store Inc. raised its stake in shares of Pfizer by 3.8% during the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after purchasing an additional 396 shares during the period. Mattern Wealth Management LLC increased its stake in Pfizer by 4.6% during the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock worth $228,000 after buying an additional 400 shares during the period. Quest Investment Management LLC increased its position in shares of Pfizer by 1.3% during the third quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company’s stock worth $809,000 after acquiring an additional 405 shares during the last quarter. Finally, Community Bank & Trust Waco Texas lifted its stake in shares of Pfizer by 0.6% in the third quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock worth $1,703,000 after acquiring an additional 412 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on PFE. TD Cowen reissued a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. UBS Group upped their target price on Pfizer from $25.00 to $27.00 and gave the company a “neutral” rating in a report on Monday, April 13th. Bank of America cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Morgan Stanley lifted their target price on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Finally, Daiwa Securities Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target on the stock. in a research report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $28.45.

Read Our Latest Stock Analysis on PFE

Pfizer Price Performance

NYSE PFE opened at $27.58 on Monday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The firm has a market capitalization of $156.83 billion, a price-to-earnings ratio of 20.28 and a beta of 0.43. The company has a 50 day simple moving average of $27.27 and a 200-day simple moving average of $26.05. Pfizer Inc. has a 52-week low of $21.87 and a 52-week high of $28.75.

Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The business’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.63 earnings per share. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Profile

(Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Read More

• Five stocks we like better than Pfizer

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).